Clinical Trial Update: High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a high infusion rate of NewGam 10% intravenous immunoglobulin in patients with primary immunodeficiency disease. The study is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Disease

Drugs mentioned

• NewGam 10% Intravenous Immunoglobulin (intravenous immunoglobulin (human) 10% solution)

Snippet

Sponsor: Octapharma | Conditions: Primary Immunodeficiency Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-03-29